Refine your search:
You can use: AND, NOT, OR, " " (exact phrase)
Search across all Transcripts:
You can use: AND, NOT, OR, " " (exact phrase)
-
... that continued development of the liver cancer market requires a multidisciplinary ... even before government reimbursement for liver cancer has been obtained. Today ... and Tarceva in combination with liver cancer. So we will get ...
-
... participate in the management of liver disease patient. Early evidence suggests ... government reimbursement. Approval for the liver cancer indication in Japan is ... and distributed for kidney and liver cancer, but some key ones ...
-
... specialties within these multidisciplinary teams that treat liver cancer. These sales specialists are concentrating on ... success factors for our continued growth for liver cancer include: First, increasing penetration in ...
-
... for deeper penetration of the liver cancer market. These specialists started ... two currently approved indications. In liver cancer, we recently announced the ... of an HCC and colorectal liver metastases also associated with a ...
-
... still-to-be-tapped potential in the global liver cancer market. The first stage ... where annual death due to liver cancer are estimated at more ... the largest prospective registry of liver cancer patients to further characterize ...
-
... to the various physician specialties that treat liver cancer patients. Initially, we utilized our established ... in the early diagnosis in treatment of liver cancer, including gastroenterologists and hepatologists, both ...
-
... country launches, following approval for liver cancer in the fourth quarter ... of patients in those settings liver cancer and hepatocellular carcinoma. But ... doxorubicin and melanoma and in liver cancer specifically. And we' ...
-
... of patients, worldwide, suffering from liver cancer. We anticipate rapid uptake ... prepare for anticipated launches in liver cancer. With our continued investment ... the Phase III Asia Pacific liver cancer trial at an upcoming ...